Navigation Links
Dr. Thomas Werner Elected to Accera, Inc.'s Board of Directors
Date:3/24/2009

BROOMFIELD, Colo., March 24 /PRNewswire/ -- Accera, Inc., a biotechnology company delivering breakthrough therapies in central nervous system (CNS) diseases, announced today that Thomas Werner, Ph.D. has been elected to its board of directors.

Since 2001, Dr. Werner has been a managing director and senior vice president of GlaxoSmithKline (GSK) and has served as CEO of the GSK Foundation until earlier this year. He led the Pharmaceutical Research Manufacturers of America (PhRMA) in Germany as its chairman through November 2008. He began his pharmaceutical career with Squibb Pharma Germany where he held sales, marketing and brand management positions from 1983-1989 and later held executive management positions at Bristol-Myers Squibb. Dr. Werner earned his Ph.D. in chemistry at the University of Gottingen in Germany.

Dr. Werner was instrumental in the successful growth strategies and leadership of the German subsidiaries of GSK and Bristol-Myers Squibb. He grew sales of the ACE inhibitor, Captopril, to become the largest pharmaceutical product in Germany, and developed Viani, an asthma drug, into one of the leading pharmaceutical products in Germany.

Dr. Werner co-founded the Genetic Research Center, a joint venture with the Max Planck Institute for Psychiatry and the Ludwig-Maximilians-University, both in Munich. He is a member of the Board of Trustees of the Paul Ehrlich Association and the Robert Koch Foundation.

"We are delighted to welcome Dr. Werner to our board of directors," said Steve Orndorff, Ph.D., Accera's founder and CEO. "Thomas has a demonstrated record of success in the management and leadership of European subsidiaries of internationally acclaimed pharmaceutical companies. With Accera's recent US product launch of Axona(TM) for Alzheimer's disease, Dr. Werner's experience in the commercialization of several highly successful drug products will be invaluable."

About Accera, Inc.

Accera, Inc., a privately held biotechnology company, discovers and develops therapeutic breakthroughs in central nervous systems disorders. Accera's novel approaches positively impact patients with neurodegenerative disorders who are in need of effective, well-tolerated therapies. Through its proprietary scientific platform, Accera is developing products that address metabolic deficiencies associated with certain neurodegenerative diseases by providing an alternative energy source for the brain. For more information, visit www.accerapharma.com.

    Contacts:                              Richard Lewis Communications, Inc.
    Accera, Inc.                           (212) 827-0020
    (303) 999-3710                         Gregory Tiberend, Media
    Steve Orndorff, Ph.D.                  gtiberend@rlcinc.com
    Founder, President and CEO             Cecelia Heer, Investors
    sorndorff@accerapharm.com              cheer@rlcinc.com


'/>"/>
SOURCE Accera, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. EUCODIS Bioscience Appoints Thomas Fischer as Chief Financial Officer
2. Peregrine Pharmaceuticals Mourns Loss of Chairman Thomas A. Waltz
3. Interface Biologics secures $5mm financing and appoints Thomas P. Reeves President and Chief Executive Officer
4. Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors
5. eResearchTechnology, Inc. to Present at the Thomas Weisel Healthcare Conference on September 4th, 2008
6. Medarex to Present at the Thomas Weisel Partners Healthcare Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Conference
8. PAREXEL International To Present at Thomas Weisel Partners Healthcare Conference
9. Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences
10. deCODE genetics to Webcast Presentation at Thomas Weisel Partners Healthcare Conference 2008
11. Volcano Presentation at Thomas Weisel Conference to Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... TURIN, Italy , April 29, 2016 ... version 5.11, the latest update to its industry-leading treatment ... has shown that Monaco version ... Users can now attain calculation speeds up to four ... Monaco . With the industry,s gold standard ...
(Date:4/28/2016)... , ... April 28, 2016 , ... ... will deliver a talk on its first-in-class technologies for tissue stem cell ... Meeting on RNAiMicroRNA Biology to Reprogramming & CRISPR-based Genome Engineering in Burlington, ...
(Date:4/27/2016)... ... 2016 , ... Shimadzu Scientific Instruments (SSI) will be showcasing ... Conference and Expo. Shimadzu’s high-performance instruments enable laboratories to test cannabis products for ... stop by booth 1021 to learn how Shimadzu’s instruments can help improve QA/QC ...
(Date:4/27/2016)... and RESEARCH TRIANGLE PARK, N.C. ... (NASDAQ: UTHR ) announced today that ... of United Therapeutics will provide an overview and update ... st Annual Health Care Conference. The ... at 10:00 a.m. Eastern Time, and can be accessed ...
Breaking Biology Technology:
(Date:3/18/2016)... 2016 --> --> ... Manned & Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance & ... the border security market and the continuing migration crisis in ... Europe has led visiongain to publish this unique ... --> defence & security companies in the border ...
(Date:3/15/2016)... , March 15, 2016 Yissum Research ... the technology-transfer company of the Hebrew University, announced today ... remote sensing technology of various human biological indicators. Neteera ... $2.0 million from private investors. ... on the detection of electromagnetic emissions from sweat ducts, ...
(Date:3/11/2016)... -- http://www.apimages.com ) - --> http://www.apimages.com ) ... AP Images ( http://www.apimages.com ) - Germany ... the new refugee identity cards. DERMALOG will be unveiling this device, ... Hanover next week.   --> Germany ... produce the new refugee identity cards. DERMALOG will be unveiling this ...
Breaking Biology News(10 mins):